Podcast #47 · 10 Feb 2026
NSCLC Treatment: Bispecific Antibodies & EGFR Mutations
- Thoracic Oncology
- Lung Cancer
- Rural Practice
- Medical Oncology
- Brain Metastasis
- Non-Small Cell Lung Cancer (NSCLC)
Bispecific antibodies are emerging as an important therapeutic class in non-small cell lung cancer (NSCLC); but how do they work, where do they fit in clinical practice, and what should oncologists be thinking about next? In this episode of Back Table Tumor Board, Dr. Kate Baker and Dr. Wade Iams from Tennessee Oncology answer these questions and more.